(Q41661752)

English

Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group

scientific article published on 2 March 2015

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

dasatinib monohydrate

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Kazuma Ohyashiki

11

object named as

Kazuma Ohyashiki

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

author name string

Noriyoshi Iriyama

1

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Shin Fujisawa

2

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Chikashi Yoshida

3

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Hisashi Wakita

4

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Shigeru Chiba

5

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Shinichiro Okamoto

6

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Kimihiro Kawakami

7

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Naoki Takezako

8

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Takashi Kumagai

9

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Koiti Inokuchi

10

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Jun Taguchi

12

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Shingo Yano

13

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Tadahiko Igarashi

14

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Yasuji Kouzai

15

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Satoshi Morita

16

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Junichi Sakamoto

17

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Hisashi Sakamaki

18

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

publication date

2 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

American Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

90

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

282-287

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chr

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23923

21 January 2018

Identifiers

10.1002/AJH.23923

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41661752&oldid=1925652801"